α-Conotoxin AuIB (trifluoroacetate salt)
(Synonyms: GCCSYPPCFATNPDC) 目录号 : GC49097
A conotoxin and an antagonist of α3β4 subunit-containing nAChRs
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
α-Conotoxin AuIB is a conotoxin that has been found in C. aulicus and has receptor antagonist and analgesic activity.1 It is a peptide antagonist of α3β4 subunit-containing nicotinic acetylcholine receptors (nAChRs; IC50 = 0.75 µM). It is greater than 100-fold selective for α3β4 subunit-containing nAChRs over those containing α2β2, α2β4, α3β2, α4β2, α4β4, or α1β1γδ subunits but does inhibit homomeric α7 nAChRs by 34% at 3 µM. Intrathecal administration of α-conotoxin AuIB (0.2 and 2 nmol/animal) reduces mechanical allodynia in a rat model of neuropathic pain induced by partial sciatic nerve ligation.2 It also reverses somatic signs of withdrawal in a mouse model of morphine withdrawal when administered intracerebroventricularly at doses of 1.75 and 3.5 pmol/animal.3
1.Luo, S., Kulak, J.M., Cartier, G.E., et al.α-Conotoxin AuIB selectively blocks α3 β4 nicotinic acetylcholine receptors and nicotine-evoked norepinephrine releaseJ. Neurosci.18(21)8571-8579(1998) 2.Napier, I.A., Klimis, H., Rycroft, B.K., et al.Intrathecal α-conotoxins Vc1.1, AuIB and MII acting on distinct nicotinic receptor subtypes reverse signs of neuropathic painNeuropharmacology62(7)2202-2207(2012) 3.Muldoon, P.P., Jackson, K.J., Perez, E., et al.The α3β4* nicotinic ACh receptor subtype mediates physical dependence to morphine: mouse and human studiesBr. J. Pharmacol.171(16)3845-3857(2014)
| Cas No. | N/A | SDF | |
| 别名 | GCCSYPPCFATNPDC | ||
| Canonical SMILES | O=C1[C@@]2([H])N(CCC2)C([C@@H](NC([C@@H](NC([C@@]3([H])NC([C@H](CSSC[C@@H](C(N[C@H](C(N[C@H](C(N[C@@](C(N[C@H](C(N4[C@](CCC4)([H])C(N[C@H](C(N[C@@H](CSSC3)C(N)=O)=O)CC(O)=O)=O)=O)CC(N)=O)=O)([H])[C@H](O)C)=O)C)=O)CC5=CC=CC=C5)=O)NC([C@@]6([H])N1CCC6)=O)NC(CN)=O)=O)=O)CO)=O)CC7=CC=C(C=C7)O)=O.OC(C(F)(F)F)=O | ||
| 分子式 | C65H89N17O21S4·XCF3COOH | 分子量 | 1572.8 |
| 溶解度 | Water: 5 mg/ml | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.6358 mL | 3.179 mL | 6.3581 mL |
| 5 mM | 0.1272 mL | 0.6358 mL | 1.2716 mL |
| 10 mM | 0.0636 mL | 0.3179 mL | 0.6358 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。